Symmetrix Pharmaceuticals

Symmetrix Pharmaceuticals was a biotechnology company focused on the development of small molecule inhibitors for the treatment of cancer. The company's primary focus was on targeting Lysine-specific demethylase 1 (LSD1), an enzyme that plays a critical role in gene expression and is often dysregulated in various malignancies. Its lead candidate, SP-2577 (seclidemstat), was developed as a potent and reversible LSD1 inhibitor specifically for Ewing sarcoma and other solid tumors. The company utilized a proprietary discovery platform to identify compounds that could effectively modulate epigenetic targets. In 2016, Salarius Pharmaceuticals acquired the intellectual property and assets related to SP-2577 from Symmetrix. Since the acquisition, the development of the pipeline has been managed by Salarius, which has advanced the lead candidate into multiple clinical trials.